Payment overview · 2025
General Payments
$1,178.40
57 reported records · 14 companies
Healthcare provider profile · identity verified
Dmitriy Ratsenberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1912950858
Verified facts
What the public records show
CMS Open Payments records show Dmitriy Ratsenberg, MD received $1,178.40 in general payments during 2025 across 57 reported records.
Sumitomo Pharma America, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Nurtec Odt, Ozempic, Prolia, Rybelsus, Ubrelvy, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 661 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 599 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $271.39 | 23.0% | 17 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $203.48 | 17.3% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $123.03 | 10.4% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.05 | 10.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $107.85 | 9.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.83 | 7.0% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $64.39 | 5.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.25 | 3.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.66 | 3.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $38.40 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.89 | 2.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.19 | 1.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.99 | 1.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.00 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,178.40 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $271.39 | 17 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $203.48 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.05 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $102.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $87.32 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $82.83 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.10 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $64.39 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.52 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.25 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 436 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 400 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 272 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 661 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 325 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 140 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 183 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
436 | 79 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
661 | 90 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
599 | 86 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
183 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
140 | 79 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
105 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
325 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1034 | 205 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1022 | 199 |
| Losartan Potassium | Losartan Potassium | 956 | 203 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 919 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 904 | 167 |
| Vascepa | Icosapent Ethyl | 761 | 111 |
| Diclofenac Sodium | Diclofenac Sodium | 735 | 136 |
| Omeprazole | Omeprazole | 685 | 120 |
| Linzess | Linaclotide | 661 | 90 |
| Synthroid | Levothyroxine Sodium | 599 | 86 |
| Metformin Hcl | Metformin Hcl | 548 | 101 |
| Gabapentin | Gabapentin | 522 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 512 | 104 |
| Dexlansoprazole Dr | Dexlansoprazole | 477 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 474 | 91 |
| Zolpidem Tartrate | Zolpidem Tartrate | 463 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 447 | 70 |
| Creon | Lipase/Protease/Amylase | 436 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 418 | 74 |
| Eliquis | Apixaban | 400 | 63 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 366 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 331 | 59 |
| Carvedilol | Carvedilol | 327 | 57 |
| Ozempic | Semaglutide | 325 | 43 |
| Mounjaro | Tirzepatide | 314 | 50 |
| Dexilant | Dexlansoprazole | 305 | 40 |
| Furosemide | Furosemide | 295 | 69 |
| Famotidine | Famotidine | 291 | 59 |
| Simvastatin | Simvastatin | 288 | 65 |
| Ezetimibe | Ezetimibe | 284 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 284 | 68 |
| Jardiance | Empagliflozin | 272 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 259 | 44 |
| Glipizide Er | Glipizide | 248 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 45 |
| Metformin Hcl Er | Metformin Hcl | 230 | 47 |
| Ibuprofen | Ibuprofen | 229 | 69 |
| Clonidine Hcl | Clonidine Hcl | 225 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 225 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 94 |
| Icosapent Ethyl | Icosapent Ethyl | 212 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 209 | 33 |
| Allopurinol | Allopurinol | 186 | 34 |
| Glimepiride | Glimepiride | 185 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 33 |
| Zenpep | Lipase/Protease/Amylase | 183 | 29 |
| Memantine Hcl | Memantine Hcl | 182 | 30 |
| Meclizine Hcl | Meclizine Hcl | 181 | 49 |
| Atenolol | Atenolol | 179 | 32 |
| Lidocaine | Lidocaine | 179 | 41 |
| Gemtesa | Vibegron | 178 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 173 | 40 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 172 | 36 |
| Lisinopril | Lisinopril | 172 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 36 |
| Meloxicam | Meloxicam | 159 | 38 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 157 | 21 |
| Valsartan | Valsartan | 156 | 24 |
| Ammonium Lactate | Ammonium Lactate | 147 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 145 | 31 |
| Azithromycin | Azithromycin | 142 | 110 |
| Xarelto | Rivaroxaban | 142 | 22 |
| Prolia | Denosumab | 140 | 79 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 136 | 43 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 135 | 15 |
| Tramadol Hcl | Tramadol Hcl | 135 | 54 |
| Tradjenta | Linagliptin | 133 | 18 |
| Donepezil Hcl | Donepezil Hcl | 130 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 124 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 122 | 28 |
| Alendronate Sodium | Alendronate Sodium | 120 | 20 |
| Dutasteride | Dutasteride | 120 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 113 | 27 |
| Crestor | Rosuvastatin Calcium | 112 | 13 |
| Lorazepam | Lorazepam | 112 | 43 |
| Montelukast Sodium | Montelukast Sodium | 112 | 17 |
| Procto-Med Hc | Hydrocortisone | 112 | 24 |
| Ranolazine Er | Ranolazine | 112 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 110 | 28 |
| Entresto | Sacubitril/Valsartan | 110 | 19 |
| Januvia | Sitagliptin Phosphate | 110 | 20 |
| Mupirocin | Mupirocin | 109 | 33 |
| Myrbetriq | Mirabegron | 106 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 106 | 20 |
| Loperamide | Loperamide Hcl | 105 | 26 |
| Nexium | Esomeprazole Magnesium | 105 | 13 |
| Alprazolam | Alprazolam | 101 | 29 |
| Farxiga | Dapagliflozin Propanediol | 100 | 16 |
| Benicar | Olmesartan Medoxomil | 99 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 82 |
| Proctozone-Hc | Hydrocortisone | 99 | 24 |
| Telmisartan | Telmisartan | 98 | 22 |
| Propranolol Hcl | Propranolol Hcl | 97 | 16 |
| Trulicity | Dulaglutide | 97 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 19 |
| Ketoconazole | Ketoconazole | 96 | 19 |
| Baclofen | Baclofen | 91 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 90 | 14 |
| Single Use Swab | Alcohol Antiseptic Pads | 89 | 34 |
| Colchicine | Colchicine | 87 | 24 |
| Trazodone Hcl | Trazodone Hcl | 87 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 17 |
| Lactulose | Lactulose | 85 | 15 |
| Alcohol Pads | Alcohol Antiseptic Pads | 84 | 33 |
| Finasteride | Finasteride | 84 | 17 |
| Mirtazapine | Mirtazapine | 83 | 15 |
| Clonazepam | Clonazepam | 82 | 27 |
| Clobetasol Propionate | Clobetasol Propionate | 80 | 15 |
| Livalo | Pitavastatin Calcium | 80 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 80 | 28 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 76 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Nitroglycerin | Nitroglycerin | 76 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 13 |
| Clotrimazole | Clotrimazole | 74 | 32 |
| Azelastine Hcl | Azelastine Hcl | 69 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 12 |
| Ztlido | Lidocaine | 69 | 16 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 68 | suppressed |
| Bystolic | Nebivolol Hcl | 67 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 11 |
| Hydrocortisone | Hydrocortisone | 66 | 27 |
| Potassium Chloride | Potassium Chloride | 66 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 64 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 23 |
| Doxepin Hcl | Doxepin Hcl | 63 | 11 |
| Memantine Hcl Er | Memantine Hcl | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | suppressed |
| Nifedipine Er | Nifedipine | 60 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 58 | 14 |
| Glipizide | Glipizide | 58 | suppressed |
| Ubrelvy | Ubrogepant | 58 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 30 |
| Ramipril | Ramipril | 55 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 54 | suppressed |
| Repatha Sureclick | Evolocumab | 54 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | 11 |
| Spironolactone | Spironolactone | 52 | suppressed |
| Celecoxib | Celecoxib | 49 | 12 |
| Constulose | Lactulose | 48 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 13 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 48 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 21 |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Mupirocin | Mupirocin Calcium | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 36 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 42 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 11 |
| Mometasone Furoate | Mometasone Furoate | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 13 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 41 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Cyclosporine | Cyclosporine | 40 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 39 | suppressed |
| Diovan | Valsartan | 38 | suppressed |
| Felodipine Er | Felodipine | 37 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 35 |
| Raloxifene Hcl | Raloxifene Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Ambien | Zolpidem Tartrate | 33 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Metronidazole | Metronidazole | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Febuxostat | Febuxostat | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Rivastigmine | Rivastigmine | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Hydroxyurea | Hydroxyurea | 27 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 27 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 25 | suppressed |
| Edarbi | Azilsartan Medoxomil | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Calcitriol | Calcitriol | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | 12 |
| Naproxen | Naproxen | 24 | 11 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Tadalafil | Tadalafil | 23 | suppressed |
| Trulance | Plecanatide | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Ibu | Ibuprofen | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Cialis | Tadalafil | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Vesicare | Solifenacin Succinate | 18 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Topiramate Er | Topiramate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Toprol Xl | Metoprolol Succinate | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Mitigare | Colchicine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 13 | suppressed |
| Cycloset | Bromocriptine Mesylate | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Glipizide Xl | Glipizide | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vimpat | Lacosamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,178.40 · 57 records | Sumitomo Pharma America, Inc. | ACCRUFER, CREON, ELIQUIS, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, LINZESS, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PROLIA, QULIPTA, REPATHA, Rybelsus, Symbravo, UBRELVY, WATCHMAN FLX, XIFAXAN, ZENPEP | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error